272 related articles for article (PubMed ID: 32578494)
1. Investigation of HDAC8-ligands' intermolecular forces through molecular dynamics simulations: profiling of non-bonding energies to design potential compounds as new anti-cancer agents.
Dewaker V; Srivastava AK; Arora A; Prabhakar YS
J Biomol Struct Dyn; 2021 Aug; 39(13):4726-4751. PubMed ID: 32578494
[TBL] [Abstract][Full Text] [Related]
2. Molecular dynamics study of HDAC8-largazole analogues co-crystals for designing potential anticancer compounds.
Dewaker V; Srivastava PN; Verma S; Prabhakar YS
J Biomol Struct Dyn; 2020 Mar; 38(4):1197-1213. PubMed ID: 30909817
[TBL] [Abstract][Full Text] [Related]
3. Examining the stability of binding modes of the co-crystallized inhibitors of human HDAC8 by molecular dynamics simulation.
Uba AI; Weako J; Keskin Ö; Gürsoy A; Yelekçi K
J Biomol Struct Dyn; 2020 Apr; 38(6):1751-1760. PubMed ID: 31057077
[TBL] [Abstract][Full Text] [Related]
4. Discovery of novel HDAC8 inhibitors from natural compounds by in silico high throughput screening.
Esther Rubavathy SM; Palanisamy K; Priyankha S; Thilagavathi R; Prakash M; Selvam C
J Biomol Struct Dyn; 2023 Nov; 41(19):9492-9502. PubMed ID: 36369945
[TBL] [Abstract][Full Text] [Related]
5. Novel urushiol derivatives as HDAC8 inhibitors: rational design, virtual screening, molecular docking and molecular dynamics studies.
Zhou H; Wang C; Deng T; Tao R; Li W
J Biomol Struct Dyn; 2018 Jun; 36(8):1966-1978. PubMed ID: 28632421
[TBL] [Abstract][Full Text] [Related]
6. Non-bonding energy directed designing of HDAC2 inhibitors through molecular dynamics simulation.
Dewaker V; Srivastava PN; Verma S; Srivastava AK; Prabhakar YS
J Biomol Struct Dyn; 2022; 40(24):13432-13455. PubMed ID: 34662251
[TBL] [Abstract][Full Text] [Related]
7. Molecular Dynamics Simulations of HDAC-ligand Complexes Towards the Design of New Anticancer Compounds.
Dewaker V; Prabhakar YS
Curr Top Med Chem; 2023; 23(29):2743-2764. PubMed ID: 37779411
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, biological evaluation and molecular docking study of arylcarboxamido piperidine and piperazine-based hydroxamates as potential HDAC8 inhibitors with promising anticancer activity.
Trivedi P; Adhikari N; Amin SA; Bobde Y; Ganesh R; Jha T; Ghosh B
Eur J Pharm Sci; 2019 Oct; 138():105046. PubMed ID: 31421254
[TBL] [Abstract][Full Text] [Related]
9. Exploring the potential binding sites of some known HDAC inhibitors on some HDAC8 conformers by docking studies.
Sixto-López Y; Gómez-Vidal JA; Correa-Basurto J
Appl Biochem Biotechnol; 2014 Aug; 173(7):1907-26. PubMed ID: 24888409
[TBL] [Abstract][Full Text] [Related]
10. Identification of novel PI3Kδ inhibitors by docking, ADMET prediction and molecular dynamics simulations.
Liu YY; Feng XY; Jia WQ; Jing Z; Xu WR; Cheng XC
Comput Biol Chem; 2019 Feb; 78():190-204. PubMed ID: 30557817
[TBL] [Abstract][Full Text] [Related]
11. Exploring the binding mechanism of HDAC8 selective inhibitors: Lessons from the modification of Cap group.
Zhang M; Ying JB; Wang SS; He D; Zhu H; Zhang C; Tang L; Lin R; Zhang Y
J Cell Biochem; 2020 Jun; 121(5-6):3162-3172. PubMed ID: 31907955
[TBL] [Abstract][Full Text] [Related]
12. A high-throughput molecular dynamics screening (HTMDS) approach to the design of novel cyclopeptide inhibitors of ATAD2B based on the non-canonical combinatorial library.
Chen Z; Li Y; Wang X; Qiu X; Wang C; Wang Z; Chen X; Wang J
J Biomol Struct Dyn; 2024 Apr; 42(6):2809-2824. PubMed ID: 37194299
[TBL] [Abstract][Full Text] [Related]
13. Combined molecular dynamics and continuum solvent approaches (MM-PBSA/GBSA) to predict noscapinoid binding to γ-tubulin dimer.
Suri C; Naik PK
SAR QSAR Environ Res; 2015 Jun; 26(6):507-19. PubMed ID: 26274780
[TBL] [Abstract][Full Text] [Related]
14. Docking and QSAR Studies of Aryl-valproic Acid Derivatives to Identify Antiproliferative Agents Targeting the HDAC8.
Martínez-Pacheco H; Ramírez-Galicia G; Vergara-Arias M; Gertsch J; Fragoso-Vazquez JM; Mendez-Luna D; Abujamra AL; Cristina CL; Cecilia RM; Mendoza-Lujambio I; Correa-Basurto J
Anticancer Agents Med Chem; 2017; 17(7):927-940. PubMed ID: 27774878
[TBL] [Abstract][Full Text] [Related]
15. Molecular docking and molecular dynamics simulations studies on β-glucosidase and xylanase
Bahaman AH; Wahab RA; Abdul Hamid AA; Abd Halim KB; Kaya Y
J Biomol Struct Dyn; 2021 Apr; 39(7):2628-2641. PubMed ID: 32248752
[TBL] [Abstract][Full Text] [Related]
16.
Joshi T; Joshi T; Sharma P; Pundir H; Chandra S
J Biomol Struct Dyn; 2021 Aug; 39(13):4816-4834. PubMed ID: 32568603
[TBL] [Abstract][Full Text] [Related]
17. A comparative study based on docking and molecular dynamics simulations over HDAC-tubulin dual inhibitors.
Hassanzadeh M; Bagherzadeh K; Amanlou M
J Mol Graph Model; 2016 Nov; 70():170-180. PubMed ID: 27750186
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic-based cancer therapeutics: new potential HDAC8 inhibitors.
Hassanzadeh M; Mahernia S; Caprini G; Fossati G; Adib M; Moakedi F; Amanlou M
J Biomol Struct Dyn; 2022 Jan; 40(1):297-311. PubMed ID: 32886033
[TBL] [Abstract][Full Text] [Related]
19. Ligand release mechanisms and channels in histone deacetylases.
Kalyaanamoorthy S; Chen YP
J Comput Chem; 2013 Oct; 34(26):2270-83. PubMed ID: 23893931
[TBL] [Abstract][Full Text] [Related]
20. Rational design of 9-vinyl-phenyl noscapine as potent tubulin binding anticancer agent and evaluation of the effects of its combination on Docetaxel.
Dash SG; Suri C; Nagireddy PKR; Kantevari S; Naik PK
J Biomol Struct Dyn; 2021 Sep; 39(14):5276-5289. PubMed ID: 32608323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
